Part 3 of Annex VI is amended as follows:
Table 3.1 is amended as follows:
the entry corresponding to index number 015-188-00-X is deleted;
the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5, 605-008-00-3 and 616-035-00-5 are replaced by the following corresponding entries:
‘006-086-00-6 | fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate | 276-696-7 | 72490-01-8 |
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 1
M = 10000
015-154-00-4 | ethephon; 2-chloroethylphosphonic acid | 240-718-3 | 16672-87-0 |
Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
Skin Corr. 1C
Aquatic Chronic 2
H311
H332
H302
H314
H411
GHS06
GHS05
GHS09
Dgr
H311
H332
H302
H314
H411
EUH071 | |
015-192-00-1 | tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate | 432-770-2 | 139189-30-3 | Skin Sens. 1 | H317 |
GHS07
Wng
H317 | | |
601-023-00-4 | ethylbenzene | 202-849-4 | 100-41-4 |
Flam. Liq. 2
Acute Tox. 4*
STOT RE 2
Asp. Tox. 1
H225
H332
H373 (hearing organs)
H304
GHS02
GHS07
GHS08
Dgr
H225
H332
H373 (hearing organs)
H304
601-026-00-0 | styrene | 202-851-5 | 100-42-5 |
Flam. Liq. 3
Repr. 2
Acute Tox. 4*
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
H226
H361d
H332
H372 (hearing organs)
H315
H319
GHS02
GHS08
GHS07
Dgr
H226
H361d
H332
H372 (hearing organs)
H315
H319
* | D
603-061-00-7 |
tetrahydro-2-furylmethanol;
tetrahydrofurfuryl alcohol
202-625-6 | 97-99-4 |
Repr. 1B
Eye Irrit. 2
H360Df
H319
GHS08
GHS07
Dgr
H360Df
H319
605-001-00-5 | formaldehyde …% | 200-001-8 | 50-00-0 |
Carc. 1B
Muta. 2
Acute Tox. 3*
Acute Tox. 3*
Acute Tox. 3*
Skin Corr. 1B
Skin Sens. 1
H350
H341
H301
H311
H331
H314
H317
GHS08
GHS06
GHS05
Dgr
H350
H341
H301
H311
H331
H314
H317
*
Skin Corr. 1B; H314: C ≥ 25 %
Skin Irrit. 2; H315: 5 % ≤ C < 25 %
Eye Irrit. 2; H319: 5 % ≤ C < 25 %
STOT SE 3; H335: C ≥ 5 %
Skin Sens. 1; H317: C ≥ 0,2 %
B, D
605-008-00-3 |
acrolein;
prop-2-enal;
acrylaldehyde
203-453-4 | 107-02-8 |
Flam. Liq. 2
Acute Tox. 1
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H225
H330
H300
H311
H314
H400
H410
GHS02
GHS06
GHS05
GHS09
Dgr
H225
H330
H300
H311
H314
H410
EUH071 |
Skin Corr. 1B;
H314: C ≥ 0,1 %
M = 100
M = 1
D
616-035-00-5 |
cymoxanil (ISO);
2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
261-043-0 | 57966-95-7 |
Repr. 2
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H361fd
H302
H373 (blood, thymus)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361fd
H302
H373 (blood, thymus)
H317
H410
M = 1
M = 1’
the following entries are inserted in accordance with the order of the entries set out in Table 3.1:
‘050-028-00-2 | 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 260-829-0 | 57583-35-4 |
Repr. 2
Acute Tox. 4
STOT RE 1
Skin Sens. 1A
H361d
H302
H372 (nervous system, immune system)
H317
GHS08
GHS07
Dgr
H361d
H302
H372 (nervous system, immune system)
H317
050-029-00-8 | dimethyltin dichloride | 212-039-2 | 753-73-1 |
Repr. 2
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
STOT RE 1
Skin Corr. 1B
H361d
H330
H301
H311
H372 (nervous system, immune system)
H314
GHS08
GHS06
GHS05
Dgr
H361d
H330
H301
H311
H372 (nervous system, immune system)
H314
EUH071 | |
601-088-00-9 | 4-vinylcyclohexene | 202-848-9 | 100-40-3 | Carc. 2 | H351 |
GHS08
Wng
H351 | | |
601-089-00-4 | muscalure; cis-tricos-9-ene | 248-505-7 | 27519-02-4 | Skin Sens. 1B | H317 |
GHS07
Wng
H317 | | |
604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 |
Repr. 2
Skin Irrit. 2
Eye Dam. 1
H361f
H315
H318
GHS08
GHS05
Dgr
H361f
H315
H318
604-091-00-3 | etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether | 407-980-2 | 80844-07-1 |
Lact.
Aquatic Acute 1
Aquatic Chronic 1
H362
H400
H410
GHS09
Wng
H362
H410
M = 100
M = 1000
606-146-00-7 | tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one | - | 87820-88-0 |
Carc. 2
Acute Tox. 4
Aquatic Chronic 2
H351
H302
H411
GHS08
GHS07
GHS09
Wng
H351
H302
H411
606-147-00-2 | cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one | 405-230-9 | 101205-02-1 | Repr. 2 | H361d |
GHS08
Wng
H361d | | |
607-705-00-8 | benzoic acid | 200-618-2 | 65-85-0 |
STOT RE 1
Skin Irrit. 2
Eye Dam. 1
H372 (lungs) (inhalation)
H315
H318
GHS08
GHS05
Dgr
H372 (lungs) (inhalation)
H315
H318
607-706-00-3 | methyl 2,5-dichlorobenzoate | 220-815-7 | 2905-69-3 |
Acute Tox. 4
STOT SE 3
Aquatic Chronic 2
H302
H336
H411
GHS07
GHS09
Wng
H302
H336
H411
612-287-00-5 | fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine | - | 79622-59-6 |
Repr. 2
Acute Tox. 4
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H361d
H332
H318
H317
H400
H410
GHS08
GHS07
GHS05
GHS09
Dgr
H361d
H332
H318
H317
H410
M = 10
M = 10
613-317-00-X | penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole | 266-275-6 | 66246-88-6 |
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H361d
H302
H400
H410
GHS08
GHS07
GHS09
Wng
H361d
H302
H410
M = 1
M = 1
613-318-00-5 | fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate | - | 473798-59-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | | |
616-212-00-7 | 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate | 259-627-5 | 55406-53-6 |
Acute Tox. 3
Acute Tox. 4
STOT RE 1
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H331
H302
H372 (larynx)
H318
H317
H400
H410
GHS06
GHS08
GHS05
GHS09
Dgr
H331
H302
H372 (larynx)
H318
H317
H410
M = 10
M = 1’
Table 3.2 is amended as follows:
the entry corresponding to index number 015-188-00-X is deleted;
the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5 and 616-035-00-5 are replaced by the following corresponding entries:
‘006-086-00-6 | fenoxycarb (ISO);ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate | 276-696-7 | 72490-01-8 |
Carc. Cat. 3; R40
N; R50-53
Xn; N
R: 40-50/53
S: (2-)22-36/37-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
015-154-00-4 | ethephon; 2-chloroethylphosphonic acid | 240-718-3 | 16672-87-0 |
C; R34
Xn; R20/21/22
N; R51-53
C; N
R: 20/21/22-34-51/53
S: (1/2-)26-36/37/39-45-61
Xi; R37: 5 % ≤ C < 10 % |
015-192-00-1 | tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate | 432-770-2 | 139189-30-3 | R43 |
Xi
R: 43
S: (2-)24-37
601-023-00-4 | ethylbenzene | 202-849-4 | 100-41-4 |
F; R11
Xn; R20-48/20-65
F; Xn
R: 11-20-48/20-65
S: (2-)16-24/25-29-62
601-026-00-0 | styrene | 202-851-5 | 100-42-5 |
Repr. Cat. 3; R63
Xn; R20-48/20
Xi; R36/38
R10
Xn
R: 10-20-36/38-48/20-63
S: (2-)23-36/37-46
Xn; R20: C ≥ 12,5 %
Xi; R36/38: C ≥ 12,5 %
D
603-061-00-7 |
tetrahydro-2-furylmethanol;
tetrahydrofurfuryl alcohol
202-625-6 | 97-99-4 |
Repr. Cat. 2; R61
Repr. Cat. 3; R62
Xi; R36
T
R: 36-61-62
S: 45-53
Xi; R36: C ≥ 10 % |
605-001-00-5 | formaldehyde …% | 200-001-8 | 50-00-0 |
Carc. Cat. 2; R45
Muta. Cat. 3; R68
T; R23/24/25
C; R34
R43
T
R: 23/24/25-34-43-45-68
S: 45-53
T; R23/24/25: C ≥ 25 %
Xn; R20/21/22: 5 % ≤ C < 25 %
C; R34: C ≥ 25 %
Xi; R36/37/38: 5 % ≤ C < 25 %
R43: C ≥ 0,2 %
B, D
616-035-00-5 |
cymoxanil (ISO);
2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
261-043-0 | 57966-95-7 |
Repr. Cat. 3; R62-63
Xn; R22-48/22
R43
N; R50-53
Xn; N
R: 22-43-48/22-62-63-50/53
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %’
the following entries are inserted in accordance with the order of the entries set out in Table 3.2:
‘050-028-00-2 | 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 260-829-0 | 57583-35-4 |
Repr. Cat. 3; R63
T; R48/25
Xn; R22
R43
T
R: 22-43-48/25-63
S: (1/2-)36/37-45
050-029-00-8 | dimethyltin dichloride | 212-039-2 | 753-73-1 |
Repr. Cat. 3; R63
T+; R26
T; R24/25-48/25
C; R34
T+
R: 24/25-26-34-48/25-63
S: (1/2-)26-28-36/37/39-45-63
601-088-00-9 | 4-vinylcyclohexene | 202-848-9 | 100-40-3 | Carc. Cat. 3; R40 |
Xn
R: 40
S: (2-)36/37
601-089-00-4 | muscalure; cis-tricos-9-ene | 248-505-7 | 27519-02-4 | R43 |
Xi
R: 43
S: (2-)24-37
604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 |
Repr. Cat. 3; R62
Xi; R38-41
Xn
R: 38-41-62
S: (2-)26-36/37/39-46
604-091-00-3 | etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether | 407-980-2 | 80844-07-1 |
R64
N; R50-53
N
R: 50/53-64
S: 60-61
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
606-146-00-7 | tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one | – | 87820-88-0 |
Carc. Cat. 3; R40
Xn; R22
N; R51-53
Xn; N
R: 22-40-51/53
S: (2-)36/37-60-61
606-147-00-2 | cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one | 405-230-9 | 101205-02-1 |
F; R11
Repr. Cat. 3; R63
F; Xn
R: 11-63
S: (2-)16-36/37-46
607-705-00-8 | benzoic acid | 200-618-2 | 65-85-0 |
T; R48/23
Xi; R38-41
T
R: 38-41-48/23
S: (1/2-)26-39-45-63
607-706-00-3 | methyl 2,5-dichlorobenzoate | 220-815-7 | 2905-69-3 |
Xn; R22
N; R51-53
Xn; N
R: 22-51/53
S: (2-) 46-61
612-287-00-5 | fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine | - | 79622-59-6 |
Repr. Cat. 3; R63
Xn; R20
Xi; R41
R43
N; R50-53
Xn; N
R: 20-41-43-50/53-63
S: (2-)26-36/37/39-46-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
613-317-00-X | penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole | 266-275-6 | 66246-88-6 |
Repr. Cat. 3; R63
Xn; R22
N; R50-53
Xn; N
R: 22-50/53-63
S: (2-) 36/37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-318-00-5 | fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate | - | 473798-59-3 | N; R51-53 |
N
R: 51/53
S: 60-61
616-212-00-7 | 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate | 259-627-5 | 55406-53-6 |
T; R23-48/23
Xn; R22
Xi; R41
R43
N; R50
T; N
R: 22-23-41-43-48/23-50
S: (1/2-)24-26-37/39-45-63
N; R50: C ≥ 2,5 %’ |